Evidence map›Paper›PMID 35925506›Full record

ArticleInfection2023

Antibody responses and correlates after two and three doses of BNT162b2 COVID-19 vaccine.

Shohei Yamamoto, Akihito Tanaka, Yusuke Oshiro, Natsumi Inamura, Tetsuya Mizoue, Norio Ohmagari, for SARS-CoV-2 Seroepidemiological Study among NCGM staff

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shohei YamamotoDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0001-6503-8577
Akihito TanakaDepartment of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
Yusuke OshiroDepartment of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
Natsumi InamuraDepartment of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
Tetsuya MizoueDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. mizoue@hosp.ncgm.go.jp.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
for SARS-CoV-2 Seroepidemiological Study among NCGM staff

Funding

Japan Health Research Promotion Bureau Research Fund 2020-B-09National Center for Global Health and Medicine 19K059
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BNT162 VaccineCOVID-19Antibodies, ViralAntibody FormationCOVID-19 VaccinesHumansAntibodies, ViralBNT162 VaccineCOVID-19 Vaccines

Identifiers

PMID35925506
PMCPMC9362369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.